Skip to content

Study · Randomized controlled trial · n = 79 · 1999

9 results

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.

Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L

Journal of clinical oncology : official journal of the American Society of Clinical Oncology1 Feb 1999Cited by 248 (Europe PMC)

PMID10080605 (opens in a new tab)DOI10.1200/jco.1999.17.2.600 (opens in a new tab)PepBankPUB-10080605
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In carcinoid syndrome, stool frequency control was similar across octreotide LAR and SC treatment groups.

    In plain wordsIn carcinoid syndrome, stool frequency control was similar across octreotide LAR and SC treatment groups.

    Peptide
    Octreotide
    Outcome
    No significant changeStool frequency control
    Study

    n = 79

    Comparator
    All octreotide treatment groups
    Outcome group
    Carcinoid Symptoms · Gastrointestinal
    Studied dose
    Dose not stated · Intramuscular LAR or subcutaneous octreotideAs given in this study (human).

    Source sentences

    Summary
    Control of stool frequency was similar in all treatment groups.
    2 context sentences
    Summary · context
    A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome.
    Summary · context
    Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In carcinoid syndrome, flushing control was best with octreotide LAR 20 mg and SC octreotide, and least effective with LAR 10 mg.

    In plain wordsIn carcinoid syndrome, flushing control was best with octreotide LAR 20 mg and SC octreotide, and worst with LAR 10 mg.

    Peptide
    Octreotide
    Outcome
    MixedFlushing control
    Study

    n = 79

    Comparator
    Other octreotide treatment groups
    Outcome group
    Carcinoid Symptoms · Gastrointestinal
    Studied dose
    Dose not stated · Intramuscular LAR or subcutaneous octreotideAs given in this study (human).

    Source sentences

    Summary
    Flushing episodes were best controlled in the 20-mg LAR and SC groups; the 10-mg LAR treatment was least effective in the control of flushing.
    2 context sentences
    Summary · context
    A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome.
    Summary · context
    Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In carcinoid syndrome, treatment success was 66.7% with octreotide LAR 10 mg versus 58.3% with SC octreotide, without a significant difference.

    In plain wordsIn carcinoid syndrome, success was 66.7% with octreotide LAR 10 mg versus 58.3% with SC octreotide, without a significant difference.

    Peptide
    Octreotide
    Outcome
    No significant changeComplete or partial treatment success
    Study

    n: not reported in source

    Comparator
    SC octreotide every 8 hours
    Outcome group
    Carcinoid Symptoms · Gastrointestinal
    Studied dose
    10 mg every 4 weeks · intramuscularAs given in this study (human).

    Measurements

    Complete or partial treatment success
    66.7%
    octreotide LAR 10 mg arm
    Complete or partial treatment success
    58.3%
    SC octreotide arm

    Source sentences

    Summary
    Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P> or =.72 for all pairwise comparisons).
    2 context sentences
    Summary · context
    A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome.
    Summary · context
    Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In carcinoid syndrome, treatment success was 71.4% with octreotide LAR 20 mg versus 58.3% with SC octreotide, without a significant difference.

    In plain wordsIn carcinoid syndrome, success was 71.4% with octreotide LAR 20 mg versus 58.3% with SC octreotide, without a significant difference.

    Peptide
    Octreotide
    Outcome
    No significant changeComplete or partial treatment success
    Study

    n: not reported in source

    Comparator
    SC octreotide every 8 hours
    Outcome group
    Carcinoid Symptoms · Gastrointestinal
    Studied dose
    20 mg every 4 weeks · intramuscularAs given in this study (human).

    Measurements

    Complete or partial treatment success
    71.4%
    octreotide LAR 20 mg arm
    Complete or partial treatment success
    58.3%
    SC octreotide arm

    Source sentences

    Summary
    Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P> or =.72 for all pairwise comparisons).
    2 context sentences
    Summary · context
    A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome.
    Summary · context
    Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In carcinoid syndrome, treatment success was 61.9% with octreotide LAR 30 mg versus 58.3% with SC octreotide, without a significant difference.

    In plain wordsIn carcinoid syndrome, success was 61.9% with octreotide LAR 30 mg versus 58.3% with SC octreotide, without a significant difference.

    Peptide
    Octreotide
    Outcome
    No significant changeComplete or partial treatment success
    Study

    n: not reported in source

    Comparator
    SC octreotide every 8 hours
    Outcome group
    Carcinoid Symptoms · Gastrointestinal
    Studied dose
    30 mg every 4 weeks · intramuscularAs given in this study (human).

    Measurements

    Complete or partial treatment success
    61.9%
    octreotide LAR 30 mg arm
    Complete or partial treatment success
    58.3%
    SC octreotide arm

    Source sentences

    Summary
    Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P> or =.72 for all pairwise comparisons).
    2 context sentences
    Summary · context
    A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome.
    Summary · context
    Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In carcinoid syndrome, treatment success was 66.7% with octreotide LAR 10 mg versus 71.4% with 20 mg, without a significant difference.

    In plain wordsIn carcinoid syndrome, success was 66.7% with octreotide LAR 10 mg versus 71.4% with 20 mg, without a significant difference.

    Peptide
    Octreotide
    Outcome
    No significant changeComplete or partial treatment success
    Study

    n: not reported in source

    Comparator
    Octreotide LAR 20 mg every 4 weeks
    Outcome group
    Carcinoid Symptoms · Gastrointestinal
    Studied dose
    10 mg every 4 weeks · intramuscularAs given in this study (human).

    Measurements

    Complete or partial treatment success
    66.7%
    octreotide LAR 10 mg arm
    Complete or partial treatment success
    71.4%
    octreotide LAR 20 mg arm

    Source sentences

    Summary
    Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P> or =.72 for all pairwise comparisons).
    2 context sentences
    Summary · context
    A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome.
    Summary · context
    Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In carcinoid syndrome, treatment success was 66.7% with octreotide LAR 10 mg versus 61.9% with 30 mg, without a significant difference.

    In plain wordsIn carcinoid syndrome, success was 66.7% with octreotide LAR 10 mg versus 61.9% with 30 mg, without a significant difference.

    Peptide
    Octreotide
    Outcome
    IncreaseComplete or partial treatment success
    Study

    n: not reported in source

    Comparator
    Octreotide LAR 30 mg every 4 weeks
    Outcome group
    Carcinoid Symptoms · Gastrointestinal
    Studied dose
    10 mg every 4 weeks · intramuscularAs given in this study (human).

    Measurements

    Complete or partial treatment success
    66.7%
    LAR 10 mg every 4 weeks
    Complete or partial treatment success
    61.9%
    LAR 30 mg every 4 weeks
    Pairwise comparison P value
    ≥ 0.72 P
    all pairwise comparisons

    Source sentences

    Summary
    Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P> or =.72 for all pairwise comparisons).
    2 context sentences
    Summary · context
    A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome.
    Summary · context
    Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In carcinoid syndrome, treatment success was 71.4% with octreotide LAR 20 mg versus 61.9% with 30 mg, without a significant difference.

    In plain wordsIn carcinoid syndrome, success was 71.4% with octreotide LAR 20 mg versus 61.9% with 30 mg, without a significant difference.

    Peptide
    Octreotide
    Outcome
    IncreaseComplete or partial treatment success
    Study

    n: not reported in source

    Comparator
    Octreotide LAR 30 mg every 4 weeks
    Outcome group
    Carcinoid Symptoms · Gastrointestinal
    Studied dose
    20 mg every 4 weeks · intramuscularAs given in this study (human).

    Measurements

    Complete or partial treatment success
    71.4%
    LAR 20 mg every 4 weeks
    Complete or partial treatment success
    61.9%
    LAR 30 mg every 4 weeks
    Pairwise comparison P value
    ≥ 0.72 P
    all pairwise comparisons

    Source sentences

    Summary
    Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P> or =.72 for all pairwise comparisons).
    2 context sentences
    Summary · context
    A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome.
    Summary · context
    Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population.
  9. 09HumanNon-randomized trialSafety outcome

    In carcinoid syndrome, patients tolerated octreotide treatment well in all four groups.

    In plain wordsIn carcinoid syndrome, patients tolerated octreotide treatment well in all four groups.

    Peptide
    Octreotide
    Outcome
    Not applicableTolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · Intramuscular LAR or subcutaneous octreotideAs given in this study (human).

    Source sentences

    Summary
    Treatment was well tolerated by patients in all four groups.
    2 context sentences
    Summary · context
    A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome.
    Summary · context
    Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.